评估olaparib在美国退伍军人转移性前列腺癌中的疗效,使用适合现实世界分析的时间无差g-rate方法
Harshraj Leuva1, Mengxi Zhou2, Nader Jamaleddine3
1University of Nebraska Medical Center, Omaha, NE, USA; James J. Peters Bronx Veterans Affairs Medical Center, Bronx, NY, USA.
EBioMedicine
|August 24, 2024
概括
在美国退伍军人中,Olaparib在转移性前列腺癌 (mPC) 和罕见突变的美国退伍军人中显示出现实世界的有效性. 一个1或更大的瘤翻倍时间比率表明生长速度减慢和生存率提高,在黑人男性中得到了相似的结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 评估olaparib在美国退伍军人转移性前列腺癌 (mPC) 的现实世界疗效.
- 评估一种用于治疗罕见瘤突变疗效的新方法.
研究的目的:
- 为了评估olaparib在美国退伍军人与mPC的现实世界的有效性.
- 用一种新的方法评估罕见突变瘤的治疗疗效.
主要方法:
- 包括139名具有mPC和同源复合修复 (HRR) 基因突变的退伍军人.
- 评估瘤生长率 (g-rate) 使用PSA值来确定瘤翻倍时间 (DT) 和DT比率.
- 假设的DT比率≥1表示治疗效益.
主要成果:
- 45%的退伍军人 (50%的黑人退伍军人) 实现了DT比率≥1.
- 对于DT比率≥1 (24.5个月) 和<1 (11.4个月) 的中位生存时间显着更长.
- 在各种HRR突变中,olaparib的疗效是一致的,不管生殖线状态或先前的治疗方法如何.
结论:
- DT比率≥1与治疗olaparib.com的mPC患者的生存率改善相关.
- 奥拉帕里布在患有mPC和HRR基因突变的退伍军人中显示出有效性,反映了临床试验结果.
- 与匹配的队列相比,恩扎胺在HRR突变瘤的第一线治疗中效率较低.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Kaplan-Meier Approach
115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115


